全髋关节和膝关节置换术中静脉血栓栓塞症药物预防的成本效益：一项系统评价 - Suppr

Suppr

超能文献

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

作者信息

Plumb Jonathan M, Clemens Andreas, Monz Brigitta U

出版信息

Pharmacoeconomics. 2010;28(9):781-2; author reply 782-4, 784-5. doi: 10.2165/11535700-000000000-00000.

DOI:10.2165/11535700-000000000-00000

PMID:20824908

Abstract

摘要

相似文献

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.全髋关节和膝关节置换术中静脉血栓栓塞症药物预防的成本效益：一项系统评价

Pharmacoeconomics. 2010;28(9):781-2; author reply 782-4, 784-5. doi: 10.2165/11535700-000000000-00000.

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.比较利伐沙班和达比加群酯与依诺肝素钠作为爱尔兰医疗保健环境下全髋关节和全膝关节置换术后血栓预防的成本效益模型。

Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.利伐沙班预防静脉血栓栓塞症：一项单一技术评估。

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07.

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.法国、意大利和西班牙全髋关节或膝关节置换术后，利伐沙班与新的和现有的预防方案预防静脉血栓栓塞的成本效益影响。

Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.依达肝素钙酯预防择期髋关节和膝关节手术患者静脉血栓栓塞症：一项单技术评估。

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.经依诺肝素间接比较，评估髋关节或膝关节置换术后利伐沙班与达比加群预防静脉血栓栓塞的效果。

J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9.

Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.信息价值分析在爱尔兰医疗保健环境下降低全髋关节置换术后血栓预防选择的决策不确定性。

Pharmacoeconomics. 2012 Oct 1;30(10):941-59. doi: 10.2165/11591510-000000000-00000.

[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].[阿哌沙班预防全膝关节或全髋关节置换术患者静脉血栓栓塞对国家卫生系统的预算影响]

Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.从美国支付者角度评估利伐沙班与依诺肝素预防术后静脉血栓栓塞的成本效果。

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

New anticoagulants as thromboprophylaxis after total hip or knee replacement.新型抗凝药物在全髋关节或膝关节置换术后的血栓预防中的应用。

Int J Technol Assess Health Care. 2013 Jul;29(3):234-43. doi: 10.1017/S0266462313000251. Epub 2013 Jun 17.

本文引用的文献

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.全髋关节和膝关节置换术后静脉血栓栓塞症药物预防的成本效益：系统评价。

Pharmacoeconomics. 2010;28(7):521-38. doi: 10.2165/11535210-000000000-00000.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.达比加群酯用于 75 岁以上或中重度肾功能损害行全膝关节或髋关节置换术患者预防静脉血栓栓塞的经济学评价。

Thromb Haemost. 2010 Feb;103(2):360-71. doi: 10.1160/TH09-08-0579. Epub 2009 Dec 18.

Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000.

Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.新型口服抗凝药在临床实践中的应用：将临床试验结果转化至骨科和普通外科患者群体

Ann Surg. 2009 Aug;250(2):219-28. doi: 10.1097/SLA.0b013e3181ae6dbe.

State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis.最新综述：评估新型抗凝剂用于大型骨科手术血栓预防的安全性概况。

Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):377-88. doi: 10.1177/1076029609338712. Epub 2009 Jul 15.

New anticoagulants: focus on venous thromboembolism.新型抗凝剂：聚焦静脉血栓栓塞症

Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. doi: 10.2174/157016109788340785.

Recent developments in the use of oral anticoagulants.口服抗凝剂使用方面的最新进展。

Expert Opin Pharmacother. 2009 Aug;10(11):1769-81. doi: 10.1517/14656560903042325.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.达比加群酯用于预防全膝关节和全髋关节置换术后静脉血栓栓塞的经济学评价

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years.全髋关节和膝关节置换手术中静脉血栓栓塞预防的成本效益：20年来健康经济模型的不断演变应用

Curr Med Res Opin. 2008 Oct;24(10):2993-3006. doi: 10.1185/03007990802443255. Epub 2008 Sep 23.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.延长疗程利伐沙班与短期依诺肝素预防全髋关节置换术后静脉血栓栓塞的双盲随机对照试验

Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验